Carol Moreno, MD, PhD, on the Phase 3 trial examining ibrutinib + rituximab versus FCR in CLL
Dr. Moreno, Hematologist, Autonomous University of Barcelona, describes the outcomes of the Phase 3 study investigating 1st line ibrutinib and rituximab versus FCR in younger chronic lymphocytic leukemia (CLL) patients presented at the 2018 ASH Annual Meeting and Exposition
Carol Moreno, MD, PhD, on how the outcomes of the illUMINTATE trial impact treatment of CLL
Dr. Moreno, Hematologist, Autonomous University of Barcelona, offers opinion on whether the outcomes of the illUMINTATE trial change the way 1st line chronic lymphocytic leukemia (CLL) is treated today
Jasmine Zain, MD, on the most exciting studies in lymphoma presented at ASH 2018
Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, shares details of the most exciting studies in lymphoma presented at the 2018 ASH Annual Meeting and Exposition
Yana Pikman, MD, regarding research outcomes from the LEAP Consortium
Dr. Pikman, Instructor in Pediatrics, Dana Farber Cancer Institute, Boston Children’s Hospital, explains how the results of the LEAP Consortium’s clinical study may help identify mutations that can improve outcomes in pediatric acute leukemia
Jasmine Zain, MD, discusses novel treatment research regarding transplants at City of Hope
Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, discusses novel treatment research regarding transplants
Jasmine Zain, MD, considers the impact of the new induction regimen in PTCL
Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, provides opinion on whether the standard of care in the treatment of peripheral T-cell lymphoma (PTCL) is changing as a result of the new induction regimen
Yana Pikman, MD, on the efforts of the LEAP Consortium in pediatric acute leukemia
Dr. Pikman, Instructor in Pediatrics, Dana Farber Cancer Institute, Boston Children’s Hospital, explains the LEAP Consortium and how the group is developing actionable genomic targets in pediatric acute leukemia
Jasmine Zain, MD, defines successful induction regimens when treating PTCL
Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, discusses what contributes to a successful induction regimen when treating peripheral T-cell lymphoma (PTCL) patients
Jasmine Zain, MD, elaborates on the investigation of novel induction regimens in PTCL
Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, tells us about the investigation of novel induction regimens prior to ASCT for the treatment of peripheral T-cell lymphoma (PTCL)
Jasmine Zain, MD, regarding the standard of care in treatment of PTCL
Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, explains how has the standard of care in the treatment of peripheral T-cell lymphoma (PTCL) has changed in the last several years
Rod A. Humerickhouse, MD, PhD, describes recent advancements in the treatment of CLL
Dr. Humerickhouse, Group Project Leader, Oncology Development, AbbVie, describes recent advancements in the treatment of chronic lymphocytic leukemia (CLL)
Rod A. Humerickhouse, MD, PhD, considers testing for minimal residual disease in CLL
Dr. Humerickhouse, Group Project Leader, Oncology Development, AbbVie, elaborates on whether chronic lymphocytic leukemia (CLL) patients should be tested for minimal residual disease (MRD)
Rod A. Humerickhouse, MD, PhD, on MRD as a surrogate marker in chronic lymphocytic leukemia
Dr. Humerickhouse, Group Project Leader, Oncology Development, AbbVie, provides opinion on whether minimal residual disease (MRD) is a legitimate surrogate marker for response and risk of recurrence in chronic lymphocytic leukemia (CLL)
Jason Butler, PhD, considers how vascular integrity impacts the leukemia-initiating metabolic switch
Dr. Butler, Associate Scientist, Regenerative Medicine and Associate Professor, Center for Discovery and Innovation, Hackensack University, discusses how vascular integrity impacts the leukemia-initiating metabolic switch
Rena Feinman, PhD, considers the the role of the microbiome in cancer & response to therapy
Dr. Feinman, Associate Scientist, Department of Research, John Theurer Cancer Center at Hackensack University Medical Center, explains why is there such an interest in the role of the microbiome in cancer and response to therapy
Jason Butler, PhD, on how age-associated aberrant MAPK signaling impacts hematopoiesis
Dr. Butler, Associate Scientist, Regenerative Medicine and Associate Professor, Center for Discovery and Innovation, Hackensack University, shares how age-associated aberrant MAPK signaling impacts hematopoiesis
Rod A. Humerickhouse, MD, PhD, regarding potential side effects from venetoclax + rituximab in CLL
Dr. Humerickhouse, Group Project Leader, Oncology Development, AbbVie, elaborates on potential concerns regarding side effects when treating chronic lymphocytic leukemia (CLL) patients with combination venetoclax and rituximab
Sen Zhuang, MD, PhD, shares the research & development philosophy at Janssen
Dr. Zhuang, VP, Oncology Clinical Research, Janssen, tells us about the research and development philosophy at Janssen Oncology Clinical Research
Rod A. Humerickhouse, MD, PhD, on treating CLL patients with venetoclax and rituximab
Dr. Humerickhouse, Group Project Leader, Oncology Development, AbbVie, tells us about the long-term outcomes when treating chronic lymphocytic leukemia (CLL) patients with venetoclax and rituximab
Sen Zhuang, MD, PhD, shares details from the LCAR-838M study in relapsed/refractory MM
Dr. Zhuang, VP, Oncology Clinical Research, Janssen, tells us about the results of the LCAR-838M study in relapsed/refractory multiple myeloma (MM) presented at the 2018 ASH Annual Meeting and Exposition
Sen Zhuang, MD, PhD, speculates on how LCAR-838M may impact the treatment of MM
Dr. Zhuang, VP, Oncology Clinical Research, Janssen, offers opinion on how LCAR-838M may impact the treatment of multiple myeloma (MM)
Sen Zhuang, MD, PhD, regarding the development of LCAR-B38M
Dr. Zhuang, VP, Oncology Clinical Research, Janssen, shares how the CAR-T product (LCAR-B38M) is being studied and how it differs from products currently on the market
Rod A. Humerickhouse, MD, PhD, elaborates on venetoclax in treatment of MM
Dr. Humerickhouse, Group Project Leader, Oncology Development, AbbVie, tells us how venetoclax should be used in the treatment of relapsed/refractory multiple myeloma (MM)
Katja Weisel, MD, provides opinion on anti-BCMA CAR-T cell therapy in multiple myeloma
Dr. Weisel, Head of the Myeloma Center, University of Tubingen, discusses anti-BCMA CAR-T cell therapy treatment for multiple myeloma (MM) patients
Habte Yimer, MD, considers the outcomes of the GRIFFIN study in multiple myeloma
Dr. Yimer, Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, tells us about the outcomes of the GRIFFIN study, a Phase 2 clinical study examining daratumumab, bortezomib, lenalidomide, and dexamethasone versus RVD in newly diagnosed multiple myeloma (MM) patients
Katja Weisel, MD, discusses current maintenance regimens in multiple myeloma
Dr. Weisel, Head of the Myeloma Center, University of Tubingen, explains how maintenance regimens in multiple myeloma may change as a result of the clinical presentations from the 2018 ASH Annual Meeting and Exposition
Habte Yimer, MD, speculates on the future of anti-BCMA CAR-T cell therapy
Dr. Yimer, Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, shares thoughts on whether anti-BCMA CAR-T cell therapy looks promising as a treatment option for multiple myeloma (MM) patients
Keith Pratz, MD, considers emerging therapies for newly diagnosed or relapsed AML patients
Dr. Pratz, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses emerging therapies for newly diagnosed or relapsed acute myelogenous leukemia (AML) patients
Katja Weisel, MD, elaborates on the outcomes of the TOURMALINE-MM3 study
Dr. Weisel, Head of the Myeloma Center, University of Tubingen, tells us how the outcomes of the TOURMALINE-MM3 study may or may not change the way she treats multiple myeloma (MM) patients
Habte Yimer, MD, regarding the POLLUX and CASTOR studies presented at ASH 2018
Dr. Yimer, Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, offers opinion on how the the POLLUX and CASTOR studies shape thinking regarding the use of daratumumab for multiple myeloma (MM) patients
Sattva Neelapu, MD, speculates on the future of CAR-T therapies in lymphoma
Dr. Neelapu, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, speculates on the future of CAR-T therapy in the treatment of lymphoma
Keith Pratz, MD, on genetic testing in AML prior to the start of therapy
Dr. Pratz, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, considers whether all newly diagnosed acute myeloid leukemia (AML) patients should undergo genetic testing prior to the start of therapy
Katja Weisel, MD, shares outcomes of the POLLUX and CASTOR studies from ASH 2018
Dr. Weisel, Head of the Myeloma Center, University of Tubingen, offers opinion on how the POLLUX and CASTOR studies shape her thinking regarding the use of daratumumab for multiple myeloma (MM) patients
Habte Yimer, MD, regarding the Lyra trial in newly diagnosed multiple myeloma presented at ASH 2018
Dr. Yimer, Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, discusses the impact of Lyra, a Phase 2 study investigating daratumumab in newly diagnosed multiple myeloma (MM) patients
Peter Vorhees, MD, describes what regimens are being used for multiple myeloma patients today
Dr. Vorhees, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute, describes what maintenance regimens are being used for multiple myeloma patients today and if that will change as a result of the clinical presentations at ASH
Peter Vorhees, MD, discusses the outcomes of the TOURMALINE-MM3 study in MM
Dr. Vorhees, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute, on if the outcomes of the TOURMALINE-MM3 study will change the way multiple myeloma patients who have had at least one prior therapy are treated
Peter Vorhees, MD, discusses outcomes of the ALCYONE trial in multiple myeloma patients
Dr. Vorhees, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute, discusses outcomes of the ALCYONE trial in transplant-ineligible newly diagnosed multiple myeloma patients
Carol Moreno, MD, PhD, discusses MRD as a legitimate surrogate marker in CLL
Dr. Moreno, Hematologist, Autonomous University of Barcelona, considers whether minimal residual disease (MRD) is a legitimate surrogate marker for response and risk of recurrence when treating chronic lymphocytic leukemia (CLL)
Carol Moreno, MD, PhD, describes recent advancements in the treatment of CLL
Dr. Moreno, Hematologist, Autonomous University of Barcelona, elaborates on recent advancements in the treatment of chronic lymphocytic leukemia (CLL)
Keith Pratz, MD, comments on the Phase I study of gilteritinib presented at ASH 2018
Dr. Pratz, Assistant Professor of Oncology, Sidney Kimmel, Comprehensive Cancer Center, Johns Hopkins University, comments on the Phase I study of gilteritinib in combination with induction and consolidation therapy in subjects with newly diagnosed acute myelogenous leukemia (AML)
Carol Moreno, MD, PhD, shares outcomes from the iLLUMINATE trial presented at ASH 2018
Dr. Moreno, Hematologist, Autonomous University of Barcelona, tells us about the outcomes of the Phase 3 iLLUMINATE trial investigating ibrutinib plus obinutuzumab for 1st line therapy of chronic lymphocytic leukemia (CLL)
Sattva Neelapu, MD, considers the use of axicabtagene ciloleucel with elderly lymphoma patients
Dr. Neelapu, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, discusses whether it is safe to use axicabtagene ciloleucel with elderly lymphoma patients
Keith Pratz, MD, regarding the reliability of the companion diagnostic test for FLT3
Dr. Pratz, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, provides opinion on the reliability of the companion diagnostic test for FLT3 and whether he feels comfortable using the test to determine a course of treatment in acute myelogenous leukemia (AML)
Sattva Neelapu, MD, on real-world experience & clinical studies examining axicabtagene ciloleucel
Dr. Neelapu, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, elaborates on how the real-world experience with axicabtagene ciloleucel compares with the previously published clinical studies of axicabtagene ciloleucel as shown in Abstract 91 at the 2018 ASH Annual Meeting and Exposition
Keith Pratz, MD, describes how gilteritinib fits into treatment algorithms for AML
Dr. Pratz, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses how newly approved gilteritinib will be incorporated into treatment plans for acute myelogenous leukemia (AML)
Sattva Neelapu, MD, regarding the ZUMA-1 two-year follow-up study in DLBCL
Dr. Neelapu, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, tells us about the ZUMA-1 two-year follow-up study of axicabtagene ciloleucel in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients presented at the 2018 ASH Annual Meeting and Exposition
James McCloskey, MD, elaborates on the role of molecular testing in newly diagnosed AML
Dr. McCloskey, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, considers whether most hematologists and oncologists are aware that molecular tests are appropriate for newly diagnosed acute myelogenous leukemia (AML) patients
Rafael Fonseca, MD, on the effectiveness of anti-BCMA CAR-T cell therapy in multiple myeloma
Dr. Fonseca, Hematologist, Mayo Clinic, considers whether anti-BCMA CAR-T cell therapy is a promising treatment option for multiple myeloma (MM) patients
James McCloskey, MD, regarding molecular testing in acute myelogenous leukemia
Dr. McCloskey, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, elaborates on how molecular tests are impacting treatment decisions for acute myelogenous leukemia (AML) patients
Rafael Fonseca, MD, discusses maintenance regimens for multiple myeloma
Dr. Fonseca, Hematologist, Mayo Clinic, shares details regarding maintenance regimens for multiple myeloma (MM) and the impact of the clinical presentations from the 2018 ASH Annual Meeting and Exposition
James McCloskey, MD, considers the application of the FLT3 test in newly diagnosed AML patients
Dr. McCloskey, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, provides opinion on whether the FLT3 test may be applied in newly diagnosed acute myelogenous leukemia (AML)
Rafael Fonseca, MD, regarding the TOURMALINE-MM3 study in multiple myeloma
Dr. Fonseca, Hematologist, Mayo Clinic, tells us how the outcomes of the TOURMALINE-MM3 study may impact the way he treats multiple myeloma (MM) patients who have had at least one prior therapy
James McCloskey, MD, describes how the FLT3 mutation influences treatment decisions in AML
Dr. McCloskey, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses how the FLT3 mutation influences treatment plans for acute myelogenous leukemia (AML)
Rafael Fonseca, MD, elaborates on the outcomes of the POLLUX and CASTOR studies in MM
Dr. Fonseca, Hematologist, Mayo Clinic, explains how the POLLUX and CASTOR studies presented at the 2018 ASH Annual Meeting and Exposition shape his thinking regarding the use of daratumumab for multiple myeloma (MM) patients
James McCloskey, MD, speculates on the reliability of the companion diagnostic test for FLT3
Dr. McCloskey, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, provides opinion on the reliability of the companion diagnostic test for FLT3 and whether the test may be used to determine treatment in acute myelogenous leukemia (AML)
Rafael Fonseca, MD, discusses frontline multiple myeloma treatment patterns
Dr. Fonseca, Hematologist, Mayo Clinic, tells us about frontline multiple myeloma (MM) treatment patterns and attrition rates in subsequent lines of therapy
Edward Copelan, MD, considers the role of allogeneic transplantation in lymphoma & multiple myeloma
Dr. Copelan, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, considers how allogeneic transplantation is being optimized for lymphoma and multiple myeloma patients and how does it compares with CAR-T therapies
Edward Copelan, MD, regarding gilteritinib for patients with FLT3+ AML
Dr. Copelan, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, on how he is currently testing acute myelogenous leukemia (AML) and how he will incorporate newly approved gilteritinib for patients with AML that are FLT3+
Nikhil Munshi, MD, discusses the outcomes of the TOURMALINE-MM3 study in multiple myeloma
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, explores how the outcomes of the TOURMALINE-MM3 study will or will not change the way multiple myeloma patients who have had at least one prior therapy are treated
Nikhil Munshi, MD, discusses the POLLUX and CASTOR studies regarding the use of daratumumab in MM
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, discusses how the POLLUX and CASTOR studies impact the use of daratumumab in multiple myeloma patients
Nikhil Munshi, MD, regarding the outcomes of the CA204-142 study from ASH 2018
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, tells us about the outcomes of the CA204-142 study investigating elotuzumab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (MM)
Nikhil Munshi, MD, considers how ID2 function impacts oncogenesis in multiple myeloma
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, explains how ID2 function impacts oncogenesis in multiple myeloma (MM)
Andrew Pecora, MD, shares his thoughts on the necessity of allogeneic transplants to MML patients
Dr. Pecora, Chief Innovation Officer, Professor and Vice President of Cancer Services John Theurer Cancer Center, shares his thoughts on if there will be a day when it may not be necessary to give an allogeneic transplant to multiple myeloma and lymphoma patients
Nizar Bahlis, MD, speculates on the future of anti-BCMA CAR-T cell therapy in MM
Dr. Bahlis, University of Calgary, Calgary, provides opinion on whether anti-BCMA CAR-T cell therapy looks promising as a treatment option for multiple myeloma (MM) patients
Nizar Bahlis, MD, describes current maintenance regimens for multiple myeloma
Dr. Bahlis, University of Calgary, Calgary, discusses current maintenance regimens for multiple myeloma (MM) and how they may change as a result of the clinical studies presented at the ASH 2018 Annual Meeting and Exposition
John Burke, MD, elaborates on the Beat AML umbrella study
Dr. Burke, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, tells us about the design, outcomes and significance of the Beat AML umbrella study
Nizar Bahlis, MD, discusses the outcomes of the TOURMALINE-MM3 study from ASH 2018
Dr. Bahlis, University of Calgary, Calgary, tells us how the outcomes of the TOURMALINE-MM3 study may change the way he treats multiple myeloma (MM)
John Burke, MD, comments on clinical research examining gilteritinib in newly diagnosed AML
Dr. Burke, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, comments on the Phase I study of gilteritinib in combination with induction and consolidation therapy in subjects with newly diagnosed acute myeloid leukemia (AML)
Nizar Bahlis, MD, regarding the impact of the POLLUX and CASTOR studies from ASH 2018
Dr. Bahlis, University of Calgary, Calgary, shares how the POLLUX and CASTOR studies presented at the 2018 ASH Annual Meeting and Exposition shape his thinking regarding the use of daratumumab in multiple myeloma (MM) treatment
John Burke, MD, elaborates on the incorporation of venetoclax into AML treatment regimens
Dr. Burke, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, explains how he plans to incorporate venetoclax into treatment regimen for acute myeloid leukemia (AML) patients
Elizabeth Budde, MD, evaluates the clinical study investigating mosunetuzumab from ASH 2018
Dr. Budde, Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, tells us about the results of the clinical study investigating mosunetuzumab, an anti-CD20/CD3 monoclonal antibody, in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) patients
John Burke, MD, speaks to the reliability of the FLT3 mutation test
Dr. Burke, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, considers whether the companion diagnostic test for FLT3 is reliable in determining a course of treatment in acute myelogenous leukemia (AML)
Elizabeth Budde, MD, on how City of Hope has overcome logistical hurdles associated with CAR-T
Dr. Budde, Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, explains how her organization has overcome some of the logistical hurdles associated with CAR-T therapies
John Burke, MD, regarding gilteritinib in acute myeloid leukemia treatment
Dr. Burke, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, elaborates on how newly approved gilteritinib will fit into treatment algorithms for patients with acute myeloid leukemia (AML)
Elizabeth Budde, MD, discusses the role of CAR-T therapies in lymphoma treatment algorithms
Dr. Budde, Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, provides opinion on how CAR-T therapies are being incorporated into treatment algorithms for lymphoma
Robert Rifkin, MD, shares his thoughts on if a rituximab biosimilar can replace rituximab
Dr. Rifkin, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, shares his thoughts on if a rituximab biosimilar can replace rituximab in follicular lymphoma treatment regimens and beyond
Robert Rifkin, MD, discusses the rationale for genetically profiling AML patients
Dr. Rifkin, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, discusses the rationale for genetically profiling Acute Myelogenous Leukemia (AML) patients, which patients should be profiled, and how actionable the results are
Robert Rifkin, MD, explains whether or not anti-BCMA CAR-T cell therapy looks promising
Dr. Rifkin, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, explains whether or not anti-BCMA CAR-T cell therapy looks promising as a treatment for multiple myeloma patients
Robert Rifkin, MD, discusses the outcomes of the TOURMALINE-MM3 study
Dr. Rifkin, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, on if the outcomes of the TOURMALINE-MM3 study will or will not change the way multiple myeloma patients are treated
Robert Rifkin, MD, talks about what clinical data could change the way multiple myeloma is treated
Dr. Rifkin, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, talks about what clinical data has been presented at ASH could change the way penta-refractory multiple myeloma patients are treated
Ravi Vij, MD, on molecular testing and acute myelogenous leukemia
Dr. Vij, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, describes how molecular tests are being incorporated into acute myelogenous leukemia (AML) treatment algorithms
Samer Khaled, MD, tells us about the MEDALIST study examining myelodysplastic syndrome
Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, describes the results of the MEDALIST study and how it will impact the way anemia is treated in myelodysplastic syndrome (MDS) patients
Ravi Vij, MD, considers anti-BCMA CAR-T cell therapy in multiple myeloma
Dr. Vij, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, considers anti-BCMA CAR-T cell therapy as a promising treatment option for multiple myeloma (MM) patients
Ravi Vij, MD, discusses current maintenance regimens for multiple myeloma
Dr. Vij, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, elaborates on current maintenance regimens for multiple myeloma patients and how clinical studies presented at ASH 2018 may influence these regimens
Samer Khaled, MD, on incorporating venetoclax into treatment regimens for AML
Dr. Khaled, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, on incorporating venetoclax into treatment regimens for acute myeloid leukemia (AML) patients
Ravi Vij, MD, shares details regarding his clinical study presented at ASH 2018
Dr. Vij, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, tells us about the outcomes of his study investigating ixazomib, revlimid, and dexamethasone consolidation
Samer Khaled, MD, regarding gilteritinib in treatment of acute myelogenous leukemia
Dr. Khaled, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, considers how he will use newly FDA approved Xospata (gilteritinib) for patients with acute myelogenous leukemia (AML)
Samer Khaled, MD, shares details of his study examining the use of CAR-T therapy in ALL
Dr. Khaled, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, tells us about the outcomes of his study examining the use of CAR-T therapy in acute lymphoblastic leukemia (ALL) at the ASH 2018 Annual Meeting and Exposition
Ravi Vij, MD, regarding the POLLUX and CASTOR clinical studies in multiple myeloma
Dr. Vij, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, elaborates on the POLLUX and CASTOR studies and whether they shape his thinking regarding the use of daratumumab in the treatment of multiple myeloma (MM)
Andrzej Jakubowiak, MD, shares thoughts on the POLLUX and CASTOR clinical studies
Dr. Jakubowiak, Professor of Medicine Director, Myeloma Program, University of Chicago Medical Center, provides opinion on how the POLLUX and CASTOR studies shaped his thinking regarding the use of daratumumab for the treatment of multiple myeloma (MM)
Andrzej Jakubowiak, MD, PhD, discusses maintenance regimens in treatment of multiple myeloma
Dr. Jakubowiak, Professor of Medicine Director, Myeloma Program, University of Chicago Medical Center, shares how maintenance regimens for multiple myeloma (MM) patients may change as a result of clinical presentations at the ASH 2018 Annual Meeting and Exposition
Andrzej Jakubowiak, MD, PhD, regarding the ALCYONE trial presented at ASH 2018
Dr. Jakubowiak, Professor of Medicine Director, Myeloma Program, University of Chicago Medical Center, tells us about the ALCYONE study examining the addition of daratumumab to bortezomib, melphalan, and prednisone in patients with transplant-ineligible newly diagnosed multiple myeloma (MM)
Andrzej Jakubowiak, MD, discusses the outcomes of the GRIFFIN study from ASH 2018
Dr. Jakubowiak, Professor of Medicine Director, Myeloma Program University of Chicago Medical Center, tells us about the outcomes of the GRIFFIN study, a Phase 2 clinical study examining daratumumab, bortezomib, lenalidomide, and dexamethasone versus RVD in newly diagnosed multiple myeloma (MM) patients
Chadi Nabhan, MD, MBA, on the role of advanced practice practitioners
Dr. Nabhan, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, discusses the role of advanced practice practitioners and why they are often challenging to recruit and retain
Chadi Nabhan, MD, MBA, shares what is being done to prevent oncologist burnout
Dr. Nabhan, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, tells us what is being done to prevent oncologist burnout and make the field more attractive to new recruits
Chadi Nabhan, MD, MBA, discusses the key factors contributing to physician burnout
Dr. Nabhan, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, shares the primary driving factors contributing to physician burnout
Chadi Nabhan, MD, MBA, regarding the risks related to two-sided payment agreements
Dr. Nabhan, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, discusses the potential risks faced by oncologists if they enter into a two-sided payment agreement with CMS
Chadi Nabhan, MD, MBA, elaborates on the skepticism regarding MACRA
Dr. Nabhan, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, considers why oncologists remain skeptical about the overall benefits of MACRA
Sundar Jagannath, MD, discusses the role of checkpoint inhibitors in treatment of MM
Dr. Jagannath, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, offers opinion on the role of checkpoint inhibitors in the treatment of multiple myeloma (MM)
Sundar Jagannath, MD, regarding proteasome inhibitors in the treatment of MM
Dr. Jagannath, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, on whether data supports the integration of proteasome inhibitors in treatment algorithms for multiple myeloma (MM)
Maria-Victoria Mateos, MD, elaborates on the TOURMALINE-MM3 presented at ASH 2018
Dr. Mateos, Associate Professor of Medicine, University of Salamanca, gives her impressions of the TOURMALINE-MM3 study presented at the 2018 ASH Annual Meeting and Exposition and whether it will change maintenance following ASCT in newly diagnosed multiple myeloma (MM) patients
Maria-Victoria Mateos, MD, on the addition of daratumumab to revlimid/dexamethasone in MM
Dr. Mateos, Associate Professor of Medicine, University of Salamanca, explains how the addition of daratumumab to revlimid/dexamethasone enhances outcomes in newly diagnosed multiple myeloma (MM) patients
Sundar Jagannath, MD, considers maintenance regimens for multiple myeloma (MM) patients
Dr. Jagannath, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, offers opinion on clinical presentations from the ASH 2018 Annual Meeting and Exposition and the influence on maintenance regimens for multiple myeloma (MM) patients
Sundar Jagannath, MD, elaborates on the outcomes of CA204-142 in MM
Dr. Jagannath, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, tells us about the outcomes of the CA204-142 study investigating elotuzumab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (MM)
Maria-Victoria Mateos, MD, regarding the CASTOR trial presented at ASH 2018
Dr. Mateos, Associate Professor of Medicine, University of Salamanca, tells us about the design and outcomes of the CASTOR study investigating bortezomib and dexamethasone +/- daratumumab in relapsed/refractory multiple myeloma
Maria-Victoria Mateos, MD, shares outcomes from the ALCYONE study in MM
Dr. Mateos, Associate Professor of Medicine, University of Salamanca, tells us about the results of the ALCYONE study looking at daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma (MM) patients
Jeff Sharman, MD, shares his thoughts on rituximab biosimilars in follicular lymphoma
Dr. Sharman, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, shares his thoughts on if a rituximab biosimilar can replace rituximab in follicular lymphoma treatment regimens and beyond
Lorenz Trumper, MD, discusses the results of ECHELON-2 in frontline PTCL
Dr. Trumper, Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of Göttingen, discusses the results of ECHELON-2 and whether the results will change the way frontline peripheral T-cell lymphoma (PTCL) patients will be treated
Jeff Sharman, MD, on the outcomes of CAPTIVATE study investigating ibrutinib and venetoclax
Dr. Sharman, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, on the outcomes of the CAPTIVATE study investigating ibrutinib and venetoclax in the treatment of front line Chronic Lymphocytic Leukemia (CLL)
Jeff Sharman, MD, on how important the CLL-14 study is in determining CLL treatment strategies
Dr. Sharman, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, explains how important the CLL-14 study is in determining Chronic Lymphocytic Leukemia (CLL) treatment strategies
Lorenz Trumper, MD, on the current standard of care for the frontline treatment of PTCL
Dr. Trumper, Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of Göttingen, discusses what the current standard of care for the frontline treatment of patients with peripheral T-cell lymphoma (PTCL)
Jeff Sharman, MD, discusses the phase 3 study investigating ibrutinib in younger CLL patients
Dr. Sharman, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, about the outcomes of the phase 3 study presented here at ASH investigating 1st line ibrutinib + rituximab versus FCR in younger Chronic Lymphocytic Leukemia (CLL) patients
Lorenz Trumper, MD, speaks on the differences between B-Cell and T-Cell lymphomas
Dr. Trumper, Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of Göttingen, speaks on the differences between B-Cell and T-Cell lymphomas and what drives the design of clinical trials
Jeff Sharman, MD, discusses the phase 3 study investigating ibrutinib in older CLL patients
Dr. Sharman, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, tells us about the outcomes of the phase 3 study presented here at ASH investigating 1st line ibrutinib +/- rituximab versus bendamustine plus rituximab in older Chronic Lymphocytic Leukemia (CLL) patients
Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL
Dr. Iyer, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, discusses improvements being made in the treatment of cutaneous T-cell lymphoma (CTCL)
Swaminathan P. Iyer, MD, shares exciting studies regarding the treatment of PTCL from ASH 2018
Dr. Iyer, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, offers opinion on impressive studies regarding the treatment of peripheral T-cell lymphoma (PTCL) presented at the 2018 ASH Annual Meeting and Exposition
Swaminathan P. Iyer, MD, on the outcomes of the ECHELON-2 study in PTCL
Dr. Iyer, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, tells us about the study design and outcomes of the ECHELON-2 study in peripheral T-cell lymphoma (PTCL)
Andre Goy, MD, comments on the long-term outcome of acalabrutinib in MCL
Dr. Goy, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, discusses the long-term outcomes of acalabrutinib in mantle cell lymphoma (MCL)
Andre Goy, MD, on immunotherapy and the treatment of hematologic malignancies
Dr. Goy, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, explains how immunotherapies are being integrated into the treatment of hematologic malignancies
Andre Goy, MD, considers checkpoint inhibitors in hematologic malignancies
Dr. Goy, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, elaborates on whether checkpoint inhibitors (i.e. ipilimumab and nivolumab) can be used as consolidation following ASCT in hematologic malignancies
Andre Goy, MD, discusses his real-world experience using axi-cel CAR-T cell therapy
Dr. Goy, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, offers opinion on his real-world experience using axicabtagene ciloleucel (axi-cel) CAR-T cell therapy to treat lymphoma
Andre Goy, MD, on research regarding the use of axi-cel CAR-T cell therapy in DLBCL
Dr. Goy, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, elaborates on the design and outcomes of a study looking at the use of axicabtagene ciloleucel (axi-cel) CAR-T cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) presented at the ASH 2018 Annual Meeting and Exposition
Tatyana Feldman, MD, regarding improvements in the treatment of CTCL
Dr. Feldman, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses improvements in the treatment of cutaneous T-cell lymphoma (CTCL) from the 2018 ASH Annual Meeting and Exposition
Tatyana Feldman, MD, on exciting studies from ASH 2018 regarding the treatment of PTCL
Dr. Feldman, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, provides opinion on impressive studies regarding the treatment of peripheral T-cell lymphoma (PTCL) presented at the 2018 ASH Annual Meeting and Exposition
Frederick Locke, MD, on whether CAR-T therapies will be expanded into solid tumors
Dr. Locke, Program Co-Leader, Immunology Moffitt Cancer Center, shares his thoughts on whether CAR-T therapies will be expanded into solid tumors
Frederick Locke, MD, on the management of toxicity withs with CAR-T therapies
Dr. Locke, Program Co-Leader, Immunology Moffitt Cancer Center, discusses how to manage toxicities with CAR-T therapies
Julie Vose, MD, on management of common toxicities with CAR-T therapies
Dr. Vose, Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, talks about the most common toxicities associated with CAR-T therapies and how to manage them
David Siegel, MD, explains the results of MM014 study presented at ASH
Dr. Siegel, Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center, explains the results of the MM014 study presented here at ASH
Julie Vose, MD, discusses improvements made in the delivery of CAR-T therapies in lymphoma
Dr. Vose, Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, discusses what improvements are being made to the delivery of CAR-T therapies to improve outcomes in the treatment of lymphoma
Frederick Locke, MD, on what improvements to turn around time with CAR-T therapies
Dr. Locke, Program Co-Leader, Immunology Moffitt Cancer Center, on what improvements to turn around time Moffitt has implemented to help make CAR-T therapies more convenient and effective
David Siegel, MD, discusses anti-BCMA CAR-T cell therapy for multiple myeloma patients
Dr. Siegel, Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center, shares his thoughts on anti-BCMA CAR-T cell therapy and if it looks promising as a treatment for multiple myeloma patients
Frederick Locke, MD, discusses how to integrate CAR-T with stem cell transplant
DR. Locke, Program Co-Leader, Immunology Moffitt Cancer Center, discusses how to integrate CAR-T with stem cell transplant and therapeutic combinations to treat lymphoma in the future
Andre Goy, MD, on responses & outcomes when treating lymphoma with CAR-T therapies
Dr. Goy, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, provides opinion on the responses and outcomes when treating lymphoma with CAR-T therapies and whether they will become a significant part of the treatment regimens
Tatyana Feldman, MD, shares outcomes of the ECHELON-2 study in PTCL
Dr. Feldman, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, tell us about the study design and outcomes of the ECHELON-2 study in peripheral T-cell lymphoma (PTCL)
David Siegel, MD, talks about the TOURMALINE-MM3 study and the treatment of multiple myeloma
Dr. Siegel, Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center, talks about how the outcomes of the TOURMALINE-MM3 study will or will not change how multiple myeloma patients are treated who have had at least one prior therapy
Tatyana Feldman, MD, offers opinion on the ECHELON-2 study in PTCL
Dr. Feldman, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, speculates on whether the ECHELON-2 study is game-changing for patients with peripheral T-cell lymphoma (PTCL)
Frederick Locke, MD, on the use of CAR-T therapies in leukemia and lymphoma
Dr. Locke, Program Co-Leader, Immunology Moffitt Cancer Center, shares his thoughts on whether CAR-T therapies are showing impressive results in leukemia and lymphoma, and if real world evidence is matching up well with clinical trial results
Tatyana Feldman, MD, on unmet needs in peripheral T-cell lymphoma (PTCL)
Dr. Feldman, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, describes unmet needs in the treatment of peripheral T-cell lymphoma (PTCL)
Julie Vose, MD, on if CAR-T therapies are showing impressive results in lymphoma
Dr. Vose, Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, explains if CAR-T therapies are showing impressive results in lymphoma, and whether real world evidence is matching up well with clinical trial results
Andrew Pecora, MD, tells us about the results of the CPIT trial presented here at ASH
Dr. Pecora, Chief Innovation Officer, Professor and Vice President of Cancer Services, John Theurer Cancer Center, tells us about the results of the CPIT trial presented here at ASH
David Siegel, MD, shares his thoughts on the daratumamab studies presented at ASH 2018
Dr. Siegel, Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center, shares his thoughts on the daratumamab studies presented at the meeting
Julie Vose, MD, tells us about the results of the AUGMENT study in relapsed/refractory indolent NHL
Dr. Vose, Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, tells us about the results of the AUGMENT study looking at lenalidomide and rituximab in the treatment of relapsed/refractory indolent Non-Hodgkin’s Lymphoma (NHL)
Julie Vose, MD, discusses whether polatuzumab improves outcomes in DLBCL patients
Dr. Vose, Professor Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, discusses whether adding polatuzumab to bendamustine and rituximab improve outcomes in diffuse large B-cell lymphoma (DLBCL) patients
Andre Goy, MD, discusses how CAR-T therapies are being integrated into the treatment of large B-Cell lymphoma
Dr. Goy, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, discusses how CAR-T therapies are being integrated into the treatment of relapsed/refractory large B-Cell lymphoma
Ravi Vij, MD, on the outcomes of the TOURMALINE-MM3 study in multiple myeloma
Ravi Vij, MD, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, shares how the outcomes of the TOURMALINE-MM3 study will impact the way he treats multiple myeloma (MM) patients
Swaminathan Padmanabhan Iyer, MD, on if ECHELON-2 study is game changing for patients with PTCL
Dr. Iyer, Professor, Department of Lymphoma and Myeloma, MD Anderson Cancer Center, on if ECHELON-2 study is game changing for patients with Peripheral T-Cell Lymphoma (PTCL)
Keith Pratz, MD, discusses venetoclax in treatment of acute myeloid leukemia (AML)
Dr. Pratz, Assistant Professor of Oncology , Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares how he plans to incorporate venetoclax into treatment regimens for acute myeloid leukemia (AML) patients
James McClosky, MD, on using newly FDA approved gilteritinib for patients with AML
Dr. McClosky, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, on using newly FDA approved gilteritinib for patients with AML
Peter Vorhees, MD, discusses the outcomes of the GRIFFIN trial in multiple myeloma
Peter Vorhees, MD, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute, discusses the outcomes of the GRIFFIN trial in multiple myeloma at ASH 2018
Follow @OBRTweets